ライフサイエンスコーパス: liver metastasis

1 ncreased liver endothelial cell adhesion and liver metastasis.

2 owing curative intent surgery for colorectal liver metastasis.

3 samples as well as association of AQP5 with liver metastasis.

4 so found to be increased in lung tissue with liver metastasis.

5 upon CCSC detection, all subjects exhibited liver metastasis.

6 topathologic findings, including parenchymal liver metastasis.

7 igh Ki67 proliferation index and presence of liver metastasis.

8 associations with recurrence, survival, and liver metastasis.

9 l ablation (RFA) in patients with colorectal liver metastasis.

10 inical utility of CS-682 in the treatment of liver metastasis.

11 ivity in vivo significantly promoted distant liver metastasis.

12 ly decreased the incidence of lymph node and liver metastasis.

13 G1 (dnG1) construct in a nude mouse model of liver metastasis.

14 provide added value in evaluating carcinoid liver metastasis.

15 y-based drug and sunitinib markedly promotes liver metastasis.

16 herapy alone for patients with breast cancer liver metastasis.

17 mour cell challenge prevented development of liver metastasis.

18 id cells on cancer cells in a mouse model of liver metastasis.

19 a (RCC), colorectal carcinoma, or colorectal liver metastasis.

20 survival in mouse models of breast and lung liver metastasis.

21 large number of patients with CRC also have liver metastasis.

22 exosomal integrin alphavbeta5 was linked to liver metastasis.

23 se expression is a consistent feature of CRC liver metastasis.

24 erapy in patients with resectable colorectal liver metastasis.

25 ociated with CRC in orthotopically generated liver metastasis.

26 by L1 overexpression in driving motility and liver metastasis.

27 eloid populations previously associated with liver metastasis.

28 F-kappaB pathway that has been implicated in liver metastasis.

29 metastasis of melanoma and MC38 colon cancer liver metastasis.

30 lantation procedures and demonstrated robust liver metastasis.

31 tastasis and also plays an important role in liver metastasis.

32 gross metastases in an intrasplenic model of liver metastasis.

33 proved respectability rates in patients with liver metastasis.

34 cant higher risk of advanced tumor stage and liver metastasis.

35 r neutrophils in the early adhesive steps of liver metastasis.

36 osurvival effect of TNF-alpha and to inhibit liver metastasis.

37 mportant role in mediating colorectal cancer liver metastasis.

38 hioate backbone in a mouse model of melanoma liver metastasis.

39 yroidal extension signified a strong risk of liver metastasis (19%, OR 23), whereas no clinical-patho

40 Of the 70 patients, 36 had colorectal liver metastasis, 24 had cholangiocarcinoma, 4 had hepat

41 te PET/CT accurately predicts the success of liver metastasis ablation at 1 y and is superior to imme

42 For women with no definite liver metastasis and at least one hepatic lesion conside

43 late TGF-beta signature accurately predicted liver metastasis and discriminated HCC cell lines by deg

44 sustaining development of colorectal cancer liver metastasis and identify a potential target for ant

45 stasis to the lung has higher TS levels than liver metastasis and is less responsive to treatment wit

46 A plasmid was an effective treatment against liver metastasis and moderately effective against lung m

47 on or using laparoscopic ultrasound (surface liver metastasis and peritoneal deposits).

48 in primary CRC significantly correlated with liver metastasis and poor patient survival.

49 at Fv-p53 treatment had a profound effect on liver metastasis and represent the first demonstration o

50 ith lung metastasis, 58 patients (8.1%) with liver metastasis, and 34 patients (4.8%) with bone metas

51 und to be upregulated in human colon cancer, liver metastasis, and melanoma progression.

52 for biomarker analysis) rate, complications, liver metastasis, and overall survival.

53 malignant pleural effusion, intraparenchymal liver metastasis, and residual tumor size were significa

54 ar survival following surgery for colorectal liver metastasis approaches 50%, over one-half of patien

55 er resection for advanced breast cancer with liver metastasis are lacking.

56 er resection for advanced breast cancer with liver metastasis are lacking.

57 recurrence following surgery for colorectal liver metastasis are limited.

58 adiofrequency ablation [RFA]) for colorectal liver metastasis between 1982 and 2008 were identified f

59 a critical role in colon cancer invasion and liver metastasis, but the mechanistic features of this p

60 w TNF signaling influences the efficiency of liver metastasis by colon and lung carcinoma in mice tha

61 Myeloid cells promote liver metastasis by down-regulating ANGPTL7 expression i

62 bition of in vitro proliferation and in vivo liver metastasis by p85alpha or p110alpha siRNA treatmen

63 were implanted with 5 x 10(6) rat colorectal liver metastasis cell line cells.

64 frequency (RF) ablation of colorectal cancer liver metastasis (CLM).

65 melanoma cells into mice resulted in reduced liver metastasis compared with CXCR4-positive uveal mela

66 aying the onset and inhibiting the growth of liver metastasis compared with gemcitabine, 5-FU, and co

67 ession of 14 genes in the primary cancer and liver metastasis compared with normal mucosa.

68 ed on a set of three human colorectal cancer liver metastasis (CRCLM) tissue sections.

69 ublished on hepatic resection for colorectal liver metastasis (CRLM) and determine whether a negative

70 For colorectal liver metastasis (CRLM), intrahepatic lymph invasion and

71 ritical for the formation and maintenance of liver metastasis derived from colorectal cancers.

72 , yet anti-lymphangiogenesis does not impact liver metastasis despite abrogating lymph node metastasi

73 verexpression potentiated local invasion and liver metastasis effects, which were suppressed by reexp

74 In a surgical model of pancreatic cancer liver metastasis, eNOS overexpression in the tumor micro

75 pecially when the time to the development of liver metastasis exceeds 2 years.

76 sendothelial migration, resulting in reduced liver metastasis formation in vivo Talin1 expression lev

77 er, our findings uncover a new mechanism for liver metastasis formation involving an active contribut

78 Despite these therapies, liver metastasis from breast cancer is associated with a

79 ng research of the mechanisms and tropism of liver metastasis from breast cancer will hopefully resul

80 Liver metastasis from colorectal cancer is a leading cau

81 spheres have been used successfully to treat liver metastasis from DSRCT.

82 esponse rates for patients with unresectable liver metastasis from solid tumors.

83 from the primary tumor to the development of liver metastasis greater than 2 years was a significant

84 ealed that CD44 knockdown increased lung and liver metastasis >10-fold, while metastasis was decrease

85 Patients with liver metastasis had worsen prognosis, conferring a 2.26

86 following surgical management of colorectal liver metastasis have largely focused on overall surviva

87 r 2; HR, 1.46), loss of appetite (HR, 1.62), liver metastasis (HR, 1.32), >/= four metastatic sites (

88 acted from normal colon, primary cancer, and liver metastasis in a patient with metastatic colon canc

89 ignaling in MSI colon cancer cells increased liver metastasis in an orthotopic model in vivo.

90 ly impaired the growth of primary tumors and liver metastasis in an orthotopic mouse model of PDAC (m

91 ic cancer cells suppressed tumorigenesis and liver metastasis in an orthotopic nude mouse model, sugg

92 stimulated tumor cell invasion, and induced liver metastasis in an orthotopic xenograft mouse model

93 cancer cells in both local colonization and liver metastasis in animal study.

94 To investigate their role, we simulated liver metastasis in C57BL/6 mice through intrasplenic in

95 ng pathway as a key mediator of invasion and liver metastasis in colon cancer.

96 at integrin alpha2 expression contributes to liver metastasis in human colorectal cancer.

97 es positively correlate with tumor grade and liver metastasis in human pancreatic neuroendocrine tumo

98 sly (SC), or in the spleen capsule to induce liver metastasis in immune-deficient mice.

99 asia to pancreatic ductal adenocarcinoma and liver metastasis in KPC mice.

100 y efficient in preventing the development of liver metastasis in mice.

101 2, reduced polyp numbers in Apc(Min/+) mice, liver metastasis in NSG mice with orthotopic tumors, and

102 Prevention of liver metastasis in vivo was tested by splenic injection

103 NFR2 antisense oligodeoxynucleotides reduced liver metastasis in wild-type mice.

104 cing lung metastasis but not affecting B16F1 liver metastasis, in fact, liver metastasis was enhanced

105 Experiments quantifying lung and liver metastasis indicate that decreased survival of IFN

106 ls from a monogenomic primary tumour and its liver metastasis indicated that a single clonal expansio

107 An in vivo model of liver metastasis induced by human gastric carcinoma was

108 al for a patient with a solitary, resectable liver metastasis is better than that for a patient with

109 idence for a role of specific mucin genes in liver metastasis is lacking.

110 Since liver metastasis is the main cause of death in cancer pa

111 Liver metastasis is the predominant cause of colorectal

112 ificantly correlated with the development of liver metastasis, its function in pancreatic cancer meta

113 he primary tumor (KMS 72; P = 0.0001) to the liver metastasis (KMS 25; tumor compared with metastasis

114 000 proteins, we found unexpectedly that all liver metastasis lesions displayed a reproducible, zonal

115 merase I in lung metastasis as compared with liver metastasis, lung tumors had a 5-fold increase in E

116 We determined that concurrent liver metastasis, lymph node metastasis, Eastern Coopera

117 The sensitivity in detecting liver metastasis, lymph nodes, bone metastasis, and prim

118 In the liver metastasis model, 5 x 10(6) LS174T cells were inje

119 To establish a CRC liver metastasis model, we implanted mouse colon tumor M

120 ir ability to metastasize in an experimental liver metastasis model.

121 carcinoma BT549 cells using the experimental liver metastasis model.

122 in combination with IL-12 in a day 3 murine liver metastasis model.

123 mor model and greater than 1.5 %ID/g for the liver metastasis model.

124 promoter (RANTES-NIS-MSC) in a colon cancer liver metastasis mouse model established by intrasplenic

125 nt SL, 95 had disseminated disease [(surface liver metastasis (n = 29) and peritoneal deposits (n = 6

126 e liver metastasis (n = 5), deep parenchymal liver metastasis (n = 4), peritoneal deposits (n = 1), n

127 l 75 had unresectable disease due to surface liver metastasis (n = 5), deep parenchymal liver metasta

128 cer: n = 1 or metastatic disease [colorectal liver metastasis]: n = 14, ovarian cancer: n = 1, gastri

129 sion profiles in primary mouse colon tumour, liver metastasis of colon cancer and naive colon tissues

130 mphangiogenic gene expression in primary and liver metastasis of colorectal cancer (CRC) and identify

131 ated with poor prognosis in both primary and liver metastasis of CRC.

132 x 10(9) PU; once a week, twice) directly to liver metastasis of five individuals with colon cancer a

133 Liver metastasis of Lewis lung carcinoma cells followed

134 ts showed that TrkBT1 overexpression induces liver metastasis of pancreatic cancer and uncovered a un

135 CD24 increases retroperitoneal invasion and liver metastasis of pancreatic cancer cells in an orthot

136 T also prevents retroperitoneal invasion and liver metastasis of pancreatic cancer cells.

137 plantation) or into the spleen (experimental liver metastasis) of nude mice.

138 interactive effects of CYP2B6 genotypes and liver metastasis on the prognosis of metastatic breast c

139 MP-1 levels were correlated with synchronous liver metastasis or distant metastasis-associated diseas

140 ver resection in patients with breast cancer liver metastasis proved to be cost-effective when compar

141 ver resection in patients with breast cancer liver metastasis proved to be cost-effective when compar

142 bone marrow (BM) in patients with colorectal liver metastasis referred to surgery.

143 onmetastatic CRC cells prevented lung and/or liver metastasis, relative to control cells that did met

144 rocess, but their prometastatic functions in liver metastasis remain incompletely understood.

145 ecreased exosome uptake, as well as lung and liver metastasis, respectively.

146 RFP cancer cells were coinjected in the PV, liver metastasis resulted that contained GFP spleen cell

147 polymerase chain reaction on a cohort of 64 liver metastasis samples from patients with complete fol

148 in colon cancer 1 (MACC1) levels measured in liver metastasis specimens to predict further recurrence

149 vanced stages of colorectal cancer (CRC) and liver metastasis, suggesting that it may play a role in

150 iagnosis, Hispanics were less likely to have liver metastasis than whites (30% v 44%, respectively; P

151 ate of patients with unresectable colorectal-liver metastasis to complete resection with hepatic-arte

152 C into these mice, was sufficient to restore liver metastasis to levels in wild-type mice.

153 Survival for patients with colorectal liver metastasis undergoing left hepatic trisectionectom

154 vival data following treatment of colorectal liver metastasis using RFA with or without hepatic resec

155 th a splenic injection model of experimental liver metastasis using syngeneic MC38 colon cancer cells

156 Liver-metastasis variants having low to high metastatic

157 eraction that enables efficient formation of liver metastasis via intrasplenic injection.

158 t affecting B16F1 liver metastasis, in fact, liver metastasis was enhanced in the absence of platelet

159 and mechanisms involved in colorectal cancer liver metastasis, which could be potential targets for d

160 leads to their escape from treatment and to liver metastasis, which in turn makes pancreatic ductal

161 also significantly inhibited lymph node and liver metastasis, which led to a significant increase in

162 Anti-angiogenesis inhibits liver metastasis, yet anti-lymphangiogenesis does not im